Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 134900
Corporate User License Price USD 6000
Corporate User License Price INR 404700
Site License Price USD 4000
Site License Price INR 269800
Request a Quote

Report Title

Oligodendroglioma-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Oligodendroglioma-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Oligodendroglioma-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Oligodendroglioma-Pipeline Review, H1 2017



Executive Summary

Oligodendroglioma-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma-Pipeline Review, H1 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.

Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 5 and 10 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology).

The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Oligodendroglioma-Overview

Oligodendroglioma-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Oligodendroglioma-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Oligodendroglioma-Companies Involved in Therapeutics Development

AngioChem Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cavion LLC

Celldex Therapeutics Inc

F. Hoffmann-La Roche Ltd

Ipsen SA

Millennium Pharmaceuticals Inc

Northwest Biotherapeutics Inc

Novartis AG

Pfizer Inc

Tocagen Inc

Oligodendroglioma-Drug Profiles

afatinib dimaleate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevacizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-1401-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Gliomas-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCVax-L-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine + TBio-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine ER + vocimagene amiretrorepvec-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride + TBio-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mibefradil dihydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paclitaxel trevatide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBX.OncV NSC-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligodendroglioma-Dormant Projects

Oligodendroglioma-Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Oligodendroglioma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Oligodendroglioma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Oligodendroglioma-Pipeline by AngioChem Inc, H1 2017

Oligodendroglioma-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Oligodendroglioma-Pipeline by Bristol-Myers Squibb Company, H1 2017

Oligodendroglioma-Pipeline by Cavion LLC, H1 2017

Oligodendroglioma-Pipeline by Celldex Therapeutics Inc, H1 2017

Oligodendroglioma-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Oligodendroglioma-Pipeline by Ipsen SA, H1 2017

Oligodendroglioma-Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Oligodendroglioma-Pipeline by Northwest Biotherapeutics Inc, H1 2017

Oligodendroglioma-Pipeline by Novartis AG, H1 2017

Oligodendroglioma-Pipeline by Pfizer Inc, H1 2017

Oligodendroglioma-Pipeline by Tocagen Inc, H1 2017

Oligodendroglioma-Dormant Projects, H1 2017

Oligodendroglioma-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AngioChem Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cavion LLC, Celldex Therapeutics Inc, F. Hoffmann-La Roche Ltd, Ipsen SA, Millennium Pharmaceuticals Inc, Northwest Biotherapeutics Inc, Novartis AG, Pfizer Inc, Tocagen Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand